BeiGene licenses solid tumor drug, matches with Ideaya’s combo plans
BeiGene said it will take on an early-stage drug for solid tumors with MTAP deletion for $150 million upfront and “time-based payments,” in a move …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
